Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Cash from Financing Activities (2023 - 2025)

Historic Cash from Financing Activities for Mereo BioPharma (MREO) over the last 3 years, with Q2 2025 value amounting to -$134000.0.

  • Mereo BioPharma's Cash from Financing Activities fell 10028.64% to -$134000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was $248000.0, marking a year-over-year decrease of 9946.31%. This contributed to the annual value of $46.1 million for FY2024, which is 47879.09% up from last year.
  • Latest data reveals that Mereo BioPharma reported Cash from Financing Activities of -$134000.0 as of Q2 2025, which was down 10028.64% from $422000.0 recorded in Q1 2025.
  • Mereo BioPharma's 5-year Cash from Financing Activities high stood at $46.8 million for Q2 2024, and its period low was -$594000.0 during Q3 2024.
  • Over the past 3 years, Mereo BioPharma's median Cash from Financing Activities value was $191000.0 (recorded in 2024), while the average stood at $9.1 million.
  • As far as peak fluctuations go, Mereo BioPharma's Cash from Financing Activities plummeted by 10751.33% in 2024, and later crashed by 10028.64% in 2025.
  • Over the past 3 years, Mereo BioPharma's Cash from Financing Activities (Quarter) stood at $7.9 million in 2023, then crashed by 100.51% to -$40000.0 in 2024, then tumbled by 235.0% to -$134000.0 in 2025.
  • Its Cash from Financing Activities stands at -$134000.0 for Q2 2025, versus $422000.0 for Q1 2025 and -$40000.0 for Q4 2024.